OptiNose (NASDAQ:OPTN) is scheduled to post its quarterly earnings results before the market opens on Thursday, March 7th. Analysts expect OptiNose to report earnings of ($0.10) per share for the quarter. The stock traded up $0.10 during trading hours on Friday, reaching $1.88. A total of 274,200 shares were exchanged, compared to the average volume of 339,445 shares. In recent news, CEO Ramy A. Mahmoud sold 52,875 shares of the company's stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $1.31, for a total transaction of $69,266.25. Insiders have sold a total of 68,994 shares of company stock worth $87,803 over the last 90 days. 2.20% of the stock is currently owned by insiders. Several institutional investors have also made changes to their holdings of OptiNose. GSA Capital Partners LLP purchased a new stake in shares of OptiNose in the fourth quarter valued at approximately $31,000. Barclays PLC boosted its stake in shares of OptiNose by 139.9% in the fourth quarter. Barclays PLC now owns 149,777 shares of the company's stock valued at $193,000 after buying an additional 87,331 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of OptiNose by 9.4% in the fourth quarter. Vanguard Group Inc. now owns 4,179,704 shares of the company's stock valued at $5,392,000 after buying an additional 358,231 shares in the last quarter. Velan Capital Investment Management LP boosted its stake in shares of OptiNose by 5.6% in the fourth quarter. Velan Capital Investment Management LP now owns 3,796,861 shares of the company's stock valued at $4,898,000 after buying an additional 200,000 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in shares of OptiNose by 9.8% during the 4th quarter. Nuveen Asset Management LLC now owns 112,190 shares of the company's stock worth $145,000 after acquiring an additional 10,000 shares in the last quarter. 57.21% of the stock is currently owned by hedge funds and other institutional investors. [50d3ee21]
Annexon (ANNX) will be releasing its quarterly earnings results on Monday, March 4th. The company has a market capitalization of $317.84 million and a PE ratio of -3.14. Annexon's CEO and EVP have recently sold shares of the company's stock. Several institutional investors have increased their stakes in ANNX. The stock has received a consensus rating of 'Buy' from six equities research analysts, with an average target price of $13.43. [368c94b7]
Eyenovia, Inc. (EYEN) reported a quarterly loss of $0.18 per share, missing the Zacks Consensus Estimate of a loss of $0.17. This represents an earnings surprise of -5.88%. The company posted zero revenues for the quarter, missing the Zacks Consensus Estimate by 99.40%. Eyenovia, Inc. shares have lost about 23.6% since the beginning of the year. The stock's performance will depend on management's commentary on the earnings call. The current consensus EPS estimate for the coming quarter is -$0.29 on $0.1 million in revenues. The company belongs to the Zacks Medical - Biomedical and Genetics industry, which is currently in the top 29% of the 250 plus Zacks industries. Another company in the same industry, Equillium, Inc., is expected to report quarterly loss of $0.19 per share, representing a year-over-year change of -337.5%. [6e3bf75f]
Nike is set to report its fiscal Q4 '24 earnings on June 27th. Sell-side consensus expects $0.84 in earnings per share, $1.54 billion in operating income, and $12.85 billion in revenue. Nike has struggled since the COVID-19 pandemic, with revenue growth at +5%, operating income growth at -8%, and EPS growth at -1% since November 2021. The company's fiscal '25 guidance will be critical, as analysts expect just 1% revenue growth for both fiscal '24 and '25. Nike's stock has been basing in the high $80s, low $90s since April. The stock will clear congestion if it can trade up and through $100, with room to run until the 50-month moving average at $120-121 per share. However, concerns about the brand's obsolescence persist, and Nike's reporting of earnings without the cash flow statement is seen as outdated. [5ee3559b]